Hepatitis C Drugs Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	151 Pages	Coherent Market Insights	January, 2024	CMI18533475

Best Price Guarantee
Price	from $4,500
Length	151 Pages
Publisher	Coherent Market Insights
Published Date	January, 2024
SKU	CMI18533475

Hepatitis C Drugs Market, By Drug Class (NS3/4A Protease Inhibitors, NS5A Inhibitors, NS5B Polymerase Inhibitors, Combination Drugs, others), By Route of Administration (Oral Drugs, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Hepatitis C is a liver infection that can lead to serious liver damage. It’s caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person’s blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C – up to 85% – the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

By Drug Class
NS3/4A Protease Inhibitors
NS5A Inhibitors
NS5B Polymerase Inhibitors
Combination Drugs
Others
By Route of Administration
Oral Drugs
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Top Companies in Hepatitis C Drugs Market:
Gilead Sciences
AbbVie
Merck & Co
Bristol-Myers Squibb
Johnson & Johnson
Hoffmann-La Roche AG
Boehringer Ingelheim
Achillion Pharmaceuticals

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Drug Class; Market Snippet, By Route of Administration; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Growing Prevalence of Hepatitis C Globally; Increasing Government Initiatives; Restraints; Increasing Adverse Effects; Opportunities; Increasing Product Availability in Various Regions; Impact Analysis; Key Highlights; Regulatory Scenario; Product launch/Approvals; PEST Analysis; PORTER’s Analysis; Merger and Acquisition Scenario
4. Hepatitis C Drugs Market– Impact of Coronavirus (COVID-19) Pandemic: COVID-19 Epidemiology; Supply Side and Demand Side Analysis; Economic Impact
5. Hepatitis C Drugs Market, By Drug Class, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019 – 2030; Segment Trends; NS3/4A Protease Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); NS5A Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); NS5B Polymerase Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Combination Drugs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
6. Hepatitis C Drugs Market, By Route of Administration, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023and 2030 (%); Y-o-Y Growth Analysis, 2019– 2030; Segment Trends; Oral Drugs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Intravenous; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
7. Hepatitis C Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023and 2030 (%); Y-o-Y Growth Analysis, 2019– 2030; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
8. Hepatitis C Drugs Market, By Region, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, By Country, 2023and 2030 (%); Y-o-Y Growth Analysis, For Country 2019–2030; Country Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); U.S.; Canada; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); U.K.; Germany; France; Italy; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); China; Japan; India; Australia; ASEAN; South Korea; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); Brazil; Mexico; Argentina; Rest of Latin America; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); South Africa; North Africa; Central Africa
9. Competitive Landscape: Gilead Sciences; Company Highlights; Product Portfolio; Key Developments; Financial Performance; Strategies; AbbVie; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Merck & Co; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Bristol-Myers Squibb; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Johnson & Johnson; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Hoffmann-La Roche AG; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Boehringer Ingelheim; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Achillion Pharmaceuticals; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Analyst Views
10. Section: Research Methodology; About us; *Browse 24 market data tables and 28 figures on “Hepatitis C Drugs Market” - Global forecast to 2030